Article
Germline Testing for Individuals with Pancreatic Adenocarcinoma and Novel Genetic Risk Factors.
Hematology/oncology clinics of North America - 1 Oct 2022
Chittenden Anu, Haraldsdottir Sigurdis, Chen Ethan, Nissim Sahar
Abstract excerpt
Germline genetic variants implicated in increasing lifetime risk of pancreatic cancer (PDAC) have been identified in ∼4% to 10% of cases. Clinical features such as family history have poor sensitivity in identifying carriers of these risk variants. Genetic testing for these germline variants has potential to guide risk assessment and surveillance recommendations in high-risk individuals to promote prevention and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
